Suchergebnisse - "Sloop, Kyle W"

PubPharm (102)

1

Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist

enthalten in: Diabetes therapy : research, treatment and education of diabetes and related disorders | 2024

von Ma, X. | Liu, R. | Pratt, E. | +3

2

Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist

enthalten in: Diabetes therapy | 2024

von Ma, X. | Liu, R. | Pratt, E. | +3

3

GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice

enthalten in: Diabetes | 2024

von Furber, E. | Hyatt, K. | Collins, K. | +14

4

Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist : A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes

enthalten in: Diabetes, obesity & metabolism | 2023

von Pratt, E. | Ma, X. | Liu, R. | +5

5

Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist : A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants

enthalten in: Diabetes, obesity & metabolism | 2023

von Pratt, E. | Ma, X. | Liu, R. | +5

6

Pancreatic islet α cell function and proliferation requires the arginine transporter SLC7A2

enthalten in: bioRxiv.org | 2023

von Spears, E. | Stanley, J. | Shou, M. | +16

7

Pancreatic islet α cell function and proliferation requires the arginine transporter SLC7A2

enthalten in: bioRxiv : the preprint server for biology | 2023

von Spears, E. | Stanley, J. | Shou, M. | +16

8

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets

enthalten in: Nature metabolism | 2023

von El, K. | Douros, J. | Willard, F. | +14

9

Orforglipron ( LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist : A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes

enthalten in: Diabetes, Obesity and Metabolism | 2023

von Pratt, E. | Ma, X. | Liu, R. | +5

10

Orforglipron ( LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist : A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants

enthalten in: Diabetes, Obesity and Metabolism | 2023

von Pratt, E. | Ma, X. | Liu, R. | +5

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]